"not expect much premium even if they do a deal". ECYT set bar for NSCLC 2b so high, reaching primary end point itself is big thing. PFS 7.1 months vs PFS 3.5months (most recent Eli lilly study). For endocyte OS will be in range of 13 to 15 monts. OS for Docetaxel alone is 9.1 months, recent Eli lilly improved OS to 10.1 months in Phase-III study.
See below Data for Eli lilly drug. There are no drugs even little closer to Endocyte. I would easily expect full sponsorship of Phase-3 trial of NSCLC and around two to three hundred m payment with Royalty.
Patients treated on the CYRAMZA-plus-docetaxel arm (n=628) achieved a median OS of 10.5 months compared to 9.1 months for patients on the placebo-plus-docetaxel arm (n=625). The OS hazard ratio was 0.86 (95% CI, 0.751-0.979, p=0.023), which corresponds to a 14 percent reduction in risk of death.
Median PFS was 4.5 months on the CYRAMZA-plus-docetaxel arm compared to 3.0 months on the placebo-plus-docetaxel arm, with a PFS hazard ratio of 0.76 (p